Cargando…
Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus
There is a close relationship between diabetes mellitus and heart failure, and diabetes is an independent risk factor for heart failure. Diabetes and heart failure are linked by not only the complication of ischemic heart disease, but also by metabolic disorders such as glucose toxicity and lipotoxi...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999085/ https://www.ncbi.nlm.nih.gov/pubmed/35408946 http://dx.doi.org/10.3390/ijms23073587 |
_version_ | 1784685106291539968 |
---|---|
author | Nakamura, Kazufumi Miyoshi, Toru Yoshida, Masashi Akagi, Satoshi Saito, Yukihiro Ejiri, Kentaro Matsuo, Naoaki Ichikawa, Keishi Iwasaki, Keiichiro Naito, Takanori Namba, Yusuke Yoshida, Masatoki Sugiyama, Hiroki Ito, Hiroshi |
author_facet | Nakamura, Kazufumi Miyoshi, Toru Yoshida, Masashi Akagi, Satoshi Saito, Yukihiro Ejiri, Kentaro Matsuo, Naoaki Ichikawa, Keishi Iwasaki, Keiichiro Naito, Takanori Namba, Yusuke Yoshida, Masatoki Sugiyama, Hiroki Ito, Hiroshi |
author_sort | Nakamura, Kazufumi |
collection | PubMed |
description | There is a close relationship between diabetes mellitus and heart failure, and diabetes is an independent risk factor for heart failure. Diabetes and heart failure are linked by not only the complication of ischemic heart disease, but also by metabolic disorders such as glucose toxicity and lipotoxicity based on insulin resistance. Cardiac dysfunction in the absence of coronary artery disease, hypertension, and valvular disease is called diabetic cardiomyopathy. Diabetes-induced hyperglycemia and hyperinsulinemia lead to capillary damage, myocardial fibrosis, and myocardial hypertrophy with mitochondrial dysfunction. Lipotoxicity with extensive fat deposits or lipid droplets is observed on cardiomyocytes. Furthermore, increased oxidative stress and inflammation cause cardiac fibrosis and hypertrophy. Treatment with a sodium glucose cotransporter 2 (SGLT2) inhibitor is currently one of the most effective treatments for heart failure associated with diabetes. However, an effective treatment for lipotoxicity of the myocardium has not yet been established, and the establishment of an effective treatment is needed in the future. This review provides an overview of heart failure in diabetic patients for the clinical practice of clinicians. |
format | Online Article Text |
id | pubmed-8999085 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89990852022-04-12 Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus Nakamura, Kazufumi Miyoshi, Toru Yoshida, Masashi Akagi, Satoshi Saito, Yukihiro Ejiri, Kentaro Matsuo, Naoaki Ichikawa, Keishi Iwasaki, Keiichiro Naito, Takanori Namba, Yusuke Yoshida, Masatoki Sugiyama, Hiroki Ito, Hiroshi Int J Mol Sci Review There is a close relationship between diabetes mellitus and heart failure, and diabetes is an independent risk factor for heart failure. Diabetes and heart failure are linked by not only the complication of ischemic heart disease, but also by metabolic disorders such as glucose toxicity and lipotoxicity based on insulin resistance. Cardiac dysfunction in the absence of coronary artery disease, hypertension, and valvular disease is called diabetic cardiomyopathy. Diabetes-induced hyperglycemia and hyperinsulinemia lead to capillary damage, myocardial fibrosis, and myocardial hypertrophy with mitochondrial dysfunction. Lipotoxicity with extensive fat deposits or lipid droplets is observed on cardiomyocytes. Furthermore, increased oxidative stress and inflammation cause cardiac fibrosis and hypertrophy. Treatment with a sodium glucose cotransporter 2 (SGLT2) inhibitor is currently one of the most effective treatments for heart failure associated with diabetes. However, an effective treatment for lipotoxicity of the myocardium has not yet been established, and the establishment of an effective treatment is needed in the future. This review provides an overview of heart failure in diabetic patients for the clinical practice of clinicians. MDPI 2022-03-25 /pmc/articles/PMC8999085/ /pubmed/35408946 http://dx.doi.org/10.3390/ijms23073587 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Nakamura, Kazufumi Miyoshi, Toru Yoshida, Masashi Akagi, Satoshi Saito, Yukihiro Ejiri, Kentaro Matsuo, Naoaki Ichikawa, Keishi Iwasaki, Keiichiro Naito, Takanori Namba, Yusuke Yoshida, Masatoki Sugiyama, Hiroki Ito, Hiroshi Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus |
title | Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus |
title_full | Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus |
title_fullStr | Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus |
title_full_unstemmed | Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus |
title_short | Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus |
title_sort | pathophysiology and treatment of diabetic cardiomyopathy and heart failure in patients with diabetes mellitus |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999085/ https://www.ncbi.nlm.nih.gov/pubmed/35408946 http://dx.doi.org/10.3390/ijms23073587 |
work_keys_str_mv | AT nakamurakazufumi pathophysiologyandtreatmentofdiabeticcardiomyopathyandheartfailureinpatientswithdiabetesmellitus AT miyoshitoru pathophysiologyandtreatmentofdiabeticcardiomyopathyandheartfailureinpatientswithdiabetesmellitus AT yoshidamasashi pathophysiologyandtreatmentofdiabeticcardiomyopathyandheartfailureinpatientswithdiabetesmellitus AT akagisatoshi pathophysiologyandtreatmentofdiabeticcardiomyopathyandheartfailureinpatientswithdiabetesmellitus AT saitoyukihiro pathophysiologyandtreatmentofdiabeticcardiomyopathyandheartfailureinpatientswithdiabetesmellitus AT ejirikentaro pathophysiologyandtreatmentofdiabeticcardiomyopathyandheartfailureinpatientswithdiabetesmellitus AT matsuonaoaki pathophysiologyandtreatmentofdiabeticcardiomyopathyandheartfailureinpatientswithdiabetesmellitus AT ichikawakeishi pathophysiologyandtreatmentofdiabeticcardiomyopathyandheartfailureinpatientswithdiabetesmellitus AT iwasakikeiichiro pathophysiologyandtreatmentofdiabeticcardiomyopathyandheartfailureinpatientswithdiabetesmellitus AT naitotakanori pathophysiologyandtreatmentofdiabeticcardiomyopathyandheartfailureinpatientswithdiabetesmellitus AT nambayusuke pathophysiologyandtreatmentofdiabeticcardiomyopathyandheartfailureinpatientswithdiabetesmellitus AT yoshidamasatoki pathophysiologyandtreatmentofdiabeticcardiomyopathyandheartfailureinpatientswithdiabetesmellitus AT sugiyamahiroki pathophysiologyandtreatmentofdiabeticcardiomyopathyandheartfailureinpatientswithdiabetesmellitus AT itohiroshi pathophysiologyandtreatmentofdiabeticcardiomyopathyandheartfailureinpatientswithdiabetesmellitus |